Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

Affiliations

¹ Addictive Behaviors Unit, Clinic Hospital, University of Barcelona, Roselló 161 Bajos, 08036, Barcelona, Spain. pbarrio@clinic.cat.
² Addictive Behaviors Unit, Clinic Hospital, University of Barcelona, Roselló 161 Bajos, 08036, Barcelona, Spain.
³ Addictive Behavior Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁴ Psychiatric Service, University of Salamanca Health Care Complex, Salamanca, Spain.
⁵ Institute of Biomedicine of Salamanca, University of Salamanca, Salamanca, Spain.
⁶ Addictive Behaviors Unit, Germanes Hospitalàries, Sant Boi, Barcelona, Spain.

Comment

Pablo Barrio et al. Clin Drug Investig. 2018 Apr.

. 2018 Apr;38(4):387-388.

doi: 10.1007/s40261-018-0625-5.

¹ Addictive Behaviors Unit, Clinic Hospital, University of Barcelona, Roselló 161 Bajos, 08036, Barcelona, Spain. pbarrio@clinic.cat.
² Addictive Behaviors Unit, Clinic Hospital, University of Barcelona, Roselló 161 Bajos, 08036, Barcelona, Spain.
³ Addictive Behavior Unit, Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁴ Psychiatric Service, University of Salamanca Health Care Complex, Salamanca, Spain.
⁵ Institute of Biomedicine of Salamanca, University of Salamanca, Salamanca, Spain.
⁶ Addictive Behaviors Unit, Germanes Hospitalàries, Sant Boi, Barcelona, Spain.

No abstract available

Comment on

Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A. Barrio P, et al. Clin Drug Investig. 2018 Feb;38(2):147-155. doi: 10.1007/s40261-017-0590-4. Clin Drug Investig. 2018. PMID: 29080208 Clinical Trial.
Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Braillon A, Taiebi F, Bernoussi A. Braillon A, et al. Clin Drug Investig. 2018 Apr;38(4):385-386. doi: 10.1007/s40261-018-0628-2. Clin Drug Investig. 2018. PMID: 29476330 No abstract available.

1. Braillon A, Taiebi F, Bernoussi A. Nalmefene phase IV study: a seeding flying in the face of evidence? Clin Drug Investig. 2018. https://doi.org/10.1007/s40261-018-0628-2 . - PubMed
1. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73:706–13. - DOI - PubMed
1. Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23:1432–42. - DOI - PubMed
1. van den Brink W, Sørensen P, Torup L, Mann K, Gual A, SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014;28:733–44. - DOI - PubMed
1. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12:e1001924. - DOI - PubMed - PMC